AA
MCID: ALP009
MIFTS: 59

Alopecia Areata (AA)

Categories: Immune diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Alopecia Areata

MalaCards integrated aliases for Alopecia Areata:

Name: Alopecia Areata 11 19 42 75 53 5 43 14 16 71 31 33
Alopecia Circumscripta 19 42
Cazenave's Vitiligo 19 71
Jonston's Alopecia 19 71
Marginal Alopecia 19 71
Celsus' Vitiligo 19 71
Diffuse Alopecia 19 71
Alopecia Celsi 19 71
Pseudopelade 71 31
Aa 19 42
Circumscribed Alopecia 11
Aa - [alopecia Areata] 33
Alopecia Cicatrisata 19
Patchy Alopecia 19
Alopecia 71
Pelade 33

Classifications:



External Ids:

Disease Ontology 11 DOID:986
ICD9CM 34 704.01
MeSH 43 D000506
SNOMED-CT 68 201131001
ICD10 31 L63 L63.9 L66.0
UMLS 71 C0002170 C0002171 C0086873 more

Summaries for Alopecia Areata

MedlinePlus Genetics: 42 Alopecia areata is a common disorder that causes hair loss. "Alopecia" is a Latin term that means baldness, and "areata" refers to the patchy nature of the hair loss that is typically seen with this condition.In most people with alopecia areata, hair falls out in small, round patches, leaving coin-sized areas of bare skin. This patchy hair loss occurs most often on the scalp but can affect other parts of the body as well. Uncommonly, the hair loss involves the entire scalp (in which case the condition is known as alopecia totalis) or the whole body (alopecia universalis). Other rare forms of alopecia areata, which have different patterns of hair loss, have also been reported.Alopecia areata affects people of all ages, although it most commonly appears in adolescence or early adulthood. Hair loss occurs over a period of weeks. The hair usually grows back after several months, although it may fall out again. In some cases, unpredictable cycles of hair loss followed by regrowth can last for years. In addition to hair loss, some affected individuals have fingernail and toenail abnormalities, such as pits on the surface of the nails.The hair loss associated with alopecia areata is not painful or disabling. However, it causes changes in a person's appearance that can profoundly affect quality of life and self-esteem. In some people, the condition can lead to depression, anxiety, and other emotional or psychological issues.

MalaCards based summary: Alopecia Areata, also known as alopecia circumscripta, is related to alopecia universalis congenita and alopecia, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia Areata is AA1 (Alopecia Areata 1), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Acetylcysteine and Cetirizine have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and homeostasis/metabolism

GARD: 19 Alopecia areata (AA) is an autoimmune disease in which the immune system mistakenly attacks the hair follicles. In most cases, hair falls out in small, round patches on the scalp. Although uncommon, hair loss can be more extensive in some people and affect other parts of the body. Although the exact cause of AA is unknown, roughly 20% of affected people have a family member with alopecia, suggesting that genetic factors may contribute to the development of the condition.

Disease Ontology: 11 An autoimmune disease resulting in the loss of hair on the scalp and elsewhere on the body initially causing bald spots.

Wikipedia: 75 Alopecia areata, also known as spot baldness, is a condition in which hair is lost from some or all... more...

Related Diseases for Alopecia Areata

Diseases in the Alopecia Areata family:

Alopecia Areata 1 Alopecia Areata 2

Diseases related to Alopecia Areata via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 849)
# Related Disease Score Top Affiliating Genes
1 alopecia universalis congenita 33.0 ULBP3 KLRK1 IL4 IL2 AIRE
2 alopecia 32.8 TNF IL4 IL2 IL1A IL17A IFNG
3 dermatitis, atopic 31.8 TNF IL4 IL2RA IL2 IL1A IL17A
4 vitiligo-associated multiple autoimmune disease susceptibility 1 31.7 TNF PTPN22 IL2 IL17A ICOSLG CTLA4
5 autoimmune disease 31.6 TNF PTPN22 KLRK1 IL4 IL2RA IL2
6 hypothyroidism 31.6 TNF PTPN22 IL4 IL2 IL17A CTLA4
7 hair disease 31.5 TNF IL2 IL17A AIRE
8 thyroiditis 31.5 TNF PTPN22 IL4 IL2 IFNG CTLA4
9 dermatitis 31.3 TNF IL4 IL2 IL1A IL17A IFNG
10 acne 31.2 TNF IL1RN IL1A IL17A
11 urticaria 31.2 TNF IL4 IL17A IFNG
12 contact dermatitis 31.2 TNF IL4 IL2 IL1RN IL1A IL17A
13 covid-19 31.1 TNF IL4 IL2RA IL2
14 allergic rhinitis 31.1 IL4 IL17A IFNG ICAM1
15 hashimoto thyroiditis 31.1 PTPN22 IL4 IL2RA IFNG ICOSLG ICAM1
16 folliculitis 31.1 TNF IL4 IL17A IFNG
17 autoimmune polyendocrine syndrome 31.1 PTPN22 IL17A ICOSLG AIRE
18 thymoma 31.0 TNF IL2 IL17A CTLA4 AIRE
19 myasthenia gravis 31.0 TNF PTPN22 IL4 IL2 IFNG CTLA4
20 lichen planus 31.0 TNF IL4 IL2 IL17A IFNG ICAM1
21 pernicious anemia 31.0 PTPN22 ICOSLG AIRE
22 graft-versus-host disease 31.0 TNF IL2 IFNG
23 pemphigus 31.0 TNF IL4 IL17A CTLA4
24 severe acute respiratory syndrome 30.9 TNF IL4 IL2 IFNG
25 spondylitis 30.9 TNF IL17A IFNG
26 allergic contact dermatitis 30.9 TNF IL4 IL2 IL17A IFNG ICOSLG
27 psoriasis 30.9 TNF PTPN22 IL4 IL2RA IL2 IL1R1
28 candidiasis 30.9 TNF IL4 IL2 IL1A IL17A IFNG
29 rhinitis 30.9 TNF IL4 IL17A IFNG ICOSLG ICAM1
30 spondyloarthropathy 1 30.9 TNF IL1RN IL1R1 IL17A ICOSLG
31 hypoadrenocorticism, familial 30.9 PTPN22 CTLA4 AIRE
32 hidradenitis 30.8 TNF IL1A IL17A IFNG
33 hidradenitis suppurativa 30.8 TNF IL1A IL17A IFNG
34 hypereosinophilic syndrome 30.8 IL4 IL2RA IL2 IFNG
35 autoimmune polyendocrine syndrome type 1 30.8 IL17A ICOSLG AIRE
36 seborrheic dermatitis 30.8 TNF IL1A IL17A
37 purpura 30.8 TNF IL4 IL2 IL17A IFNG
38 irritant dermatitis 30.7 TNF IL4 IL1A IL17A
39 tonsillitis 30.7 TNF IL4 IL2 IL1A IFNG
40 systemic scleroderma 30.7 TNF IL4 IL2 IL17A ICOSLG
41 crohn's disease 30.7 TNF IL4 IL2 IL17A IFNG ICOSLG
42 lymphopenia 30.7 PTPN22 IL4 IL2RA IL2 IFNG CTLA4
43 exanthem 30.7 TNF IL4 IL2 IL17A IFNG ICOSLG
44 psoriatic arthritis 30.7 TNF PTPN22 IL1RN IL1R1 IL1A IL17A
45 severe combined immunodeficiency 30.7 TNF IL4 IL2RA IL2 IL1RN IL17A
46 allergic asthma 30.6 IL4 IL17A IFNG ICAM1 CTLA4
47 vasculitis 30.6 TNF IL17A ICAM1 CTLA4
48 ulcerative colitis 30.6 TNF IL4 IL2 IL1RN IL1R1 IL17A
49 conjunctivitis 30.6 TNF IL4 IL2RA IL2 IFNG ICAM1
50 sezary's disease 30.6 IL4 IL2RA IL2 IFNG CTLA4

Graphical network of the top 20 diseases related to Alopecia Areata:



Diseases related to Alopecia Areata

Symptoms & Phenotypes for Alopecia Areata

UMLS symptoms related to Alopecia Areata:


pruritus; exanthema

GenomeRNAi Phenotypes related to Alopecia Areata according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 GZMB IL17A IL1A IL2RA TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 GZMB ICAM1 IL17A IL2 IL2RA TNF
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.4 ICAM1

MGI Mouse Phenotypes related to Alopecia Areata:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 AIRE CTLA4 GZMB ICAM1 ICOSLG IFNG
2 immune system MP:0005387 10.25 AIRE CTLA4 GZMB ICAM1 ICOSLG IFNG
3 digestive/alimentary MP:0005381 10.15 AIRE CTLA4 ICAM1 IFNG IL17A IL1R1
4 endocrine/exocrine gland MP:0005379 10.14 AIRE CTLA4 ICAM1 IFNG IL17A IL1R1
5 neoplasm MP:0002006 10.13 AIRE GZMB ICAM1 IFNG IL1A IL1R1
6 liver/biliary system MP:0005370 10.11 AIRE CTLA4 IFNG IL17A IL1R1 IL2
7 hematopoietic system MP:0005397 10.06 AIRE CTLA4 GZMB ICAM1 ICOSLG IFNG
8 respiratory system MP:0005388 10 AIRE CTLA4 IFNG IL17A IL1R1 IL2
9 mortality/aging MP:0010768 9.83 AIRE CTLA4 GZMB ICAM1 IFNG IL17A
10 integument MP:0010771 9.32 CTLA4 ICAM1 IFNG IL17A IL1A IL1R1

Drugs & Therapeutics for Alopecia Areata

Drugs for Alopecia Areata (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 251)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
2
Cetirizine Approved Phase 4 83881-51-0 2678
3
Histamine Approved, Investigational Phase 4 51-45-6 774
4
Apremilast Approved, Investigational Phase 4 608141-41-9 10151715 11561674
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
10
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
11
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
12
Hydroxychloroquine Approved Phase 4 118-42-3 3652
13
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
14
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 2791 5311051 32798
15
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
16
Fluocinonide Approved, Investigational Phase 4 356-12-7 9642
17
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
18
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
19
Cysteine Approved, Nutraceutical Phase 4 52-90-4 594 5862
20
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
21 Emollients Phase 4
22 Anti-Allergic Agents Phase 4
23 N-monoacetylcystine Phase 4
24
Histamine phosphate Phase 4 51-74-1 134614
25 Histamine H1 Antagonists, Non-Sedating Phase 4
26 Histamine H1 Antagonists Phase 4
27 Histamine Antagonists Phase 4
28 Anti-Infective Agents Phase 4
29 Analgesics Phase 4
30 Phosphodiesterase 4 Inhibitors Phase 4
31 Anti-Inflammatory Agents, Non-Steroidal Phase 4
32 Analgesics, Non-Narcotic Phase 4
33 Adjuvants, Immunologic Phase 4
34
Methylprednisolone Acetate Phase 4 584547
35 Antiprotozoal Agents Phase 4
36 Antiparasitic Agents Phase 4
37 Antimalarials Phase 4
38 Anesthetics Phase 4
39 Antineoplastic Agents, Hormonal Phase 4
40 Neuroprotective Agents Phase 4
41 Anti-Arrhythmia Agents Phase 4
42 Sodium Channel Blockers Phase 4
43 Anesthetics, Local Phase 4
44 Antibiotics, Antitubercular Phase 4
45 Anti-Bacterial Agents Phase 4
46 Anti-Asthmatic Agents Phase 4
47 Respiratory System Agents Phase 4
48 Betamethasone-17,21-dipropionate Phase 4
49
Betamethasone Valerate Phase 4 2152-44-5
50
Betamethasone sodium phosphate Phase 4

Interventional clinical trials:

(show top 50) (show all 401)
# Name Status NCT ID Phase Drugs
1 Does Carboxytherapy Play a Role in Alopecia Areata Either Solely or in Combination? Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids Unknown status NCT04228029 Phase 4 Intralesional Steroid Injection
2 Efficacy of Fractional CO2 Laser Alone and as Transepidermal Drug Delivery for Different Modalities of Treatment in Alopecia Areata Unknown status NCT04003376 Phase 4 Triamcinolone Acetonide 10mg/mL;vitamin D solution
3 Modified SALT Score for Assessment of Alopecia Areata Unknown status NCT04412148 Phase 4 Triamcinolone Acetonide
4 Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation Unknown status NCT03473600 Phase 4 Triamcinolone acetonide injection
5 Efficacy and Tolerability of N-Acetyl- Cysteine for Treatment of The Early-onset Androgenetic Alopecia in Men Unknown status NCT04209803 Phase 4 Minoxidil 5% topically and oral NAC 600 mg
6 Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Unknown status NCT04293822 Phase 4 Cetirizine;Minoxidil
7 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
8 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Unknown status NCT03388840 Phase 4
9 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
10 Open Label Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Unknown status NCT03422640 Phase 4 Apremilast
11 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Completed NCT03800979 Phase 4 Tofacitinib
12 Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin Completed NCT00176969 Phase 4 Capsaicin
13 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
14 Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
15 Phenotype and Cytokine Production Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Aldara 5% Cream Using Flow Cytometry Completed NCT00176943 Phase 4 Aldara Cream 5%
16 Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial Completed NCT03535233 Phase 4 Triamcinolone Acetonide;Minoxidil 5 % Topical Spray;clobetasol propionate
17 A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
18 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate
19 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
20 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Completed NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
21 Minoxidil in Treatment of Androgenetic Alopecia Completed NCT04090801 Phase 4 Topical minoxidil 5% in 90% ethanol and 5% propylene glycol;Topical minoxidil 5% in pure ethanol alone
22 An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Completed NCT03521687 Phase 4 Apremilast
23 Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata: a Pilot Study of Patient Tolerability Recruiting NCT05278858 Phase 4
24 Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study Recruiting NCT04207931 Phase 4 Topical steroid class I-II;Triamcinolone Acetonide;Doxycyline;Minoxidil
25 The Use of Hydradermabrasion in the Scalp to Improve Scalp Health and Improve Outcomes in Androgenetic Alopecia Recruiting NCT05426629 Phase 4
26 The Efficacy of Combining 308 Nm-Excimer Light and Topical Steroid in the Treatment of Alopecia Areata Not yet recruiting NCT04793945 Phase 4
27 A Phase 4 Multicenter, Randomized, Placebo Controlled Trial of 3 Doses of Intralesional Triamcinolone (KENALOG®) In the Treatment of Mild to Moderate Patch Type Alopecia Areata Terminated NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
28 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
29 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
30 TREg Activation in the Treatment of the PELADE (Alopecia Areata). Double Blind Randomized Placebo Controlled Comparative Study Using Low Doses of IL2 Completed NCT02557074 Phase 3 IL2;placebo
31 A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS Completed NCT03732807 Phase 2, Phase 3 PF-06651600 Induction Dose;PF-06651600 Maintenance Dose #1;PF-06651600 Maintenance Dose #2;PF-06651600 Maintenance Dose #3;Placebo
32 A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata Completed NCT04797650 Phase 3 CTP-543, 8 mg BID;CTP-543, 12 mg BID;Placebo, BID
33 A Two Stage Phase II Randomized Bilateral Comparison of Topical Targretin® Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
34 A Randomized Controlled Trial of Clobetasol Propionate 0.05% Cream Versus Hydrocortisone 1% Cream in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
35 A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata Completed NCT04518995 Phase 3 CTP-543, 8 mg BID;CTP-543, 12 mg BID;Placebo, BID
36 RANDOMIZED DOUBLE-BLIND STUDY MULTICENTRIQUE TESTING THE EFFICIENCY OF the METHOTREXATE AT PATIENTS AFFECTED BY GRAVE PELADE (METHOTREXATE VERSUS PLACEBO WITH SECONDARY TREATMENT BY METHOTREXATE and PREDNISONE) Completed NCT02037191 Phase 3 Methotrexate;Placebo
37 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
38 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia Completed NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical vehicle solution
39 Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study Completed NCT03753113 Phase 3 Topical Herbal Solution;Topical Minoxidil 5%
40 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
41 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
42 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
43 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
44 A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males Completed NCT00151515 Phase 3 minoxidil
45 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
46 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
47 Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia: A Randomized, Double-blind Clinical Trial Completed NCT05296863 Phase 3
48 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
49 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
50 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo

Search NIH Clinical Center for Alopecia Areata

Inferred drug relations via UMLS 71 / NDF-RT 50 :


D-BIOTIN
Finasteride
Minoxidil

Cochrane evidence based reviews: alopecia areata

Genetic Tests for Alopecia Areata

Anatomical Context for Alopecia Areata

Organs/tissues related to Alopecia Areata:

MalaCards : Skin, Breast, T Cells, Brain, Prostate, Thyroid, Bone Marrow

Publications for Alopecia Areata

Articles related to Alopecia Areata:

(show top 50) (show all 5090)
# Title Authors PMID Year
1
Immunopathogenesis of folliculitis decalvans: clues in early lesions. 53 62
18794044 2008
2
[Regulatory effect of procyanidins on the expressions of interferon-gamma, interleukin-12 and transcription factor T-bet mRNA in peripheral blood mononuclear cell of patients with alopecia areata]. 53 62
19123327 2008
3
The autoimmune regulator gene (AIRE) is strongly associated with vitiligo. 53 62
18616774 2008
4
Genetic analysis of autoimmune regulator haplotypes in alopecia areata. 53 62
18194361 2008
5
In vivo levels of IL-4, IL-10, TGF-beta1 and IFN-gamma mRNA of the peripheral blood mononuclear cells in patients with alopecia areata in comparison to those in patients with atopic dermatitis. 53 62
17021766 2007
6
Investigation of the p.Ser278Arg polymorphism of the autoimmune regulator (AIRE) gene in alopecia areata. 53 62
16774540 2006
7
[Interferon-gamma and neopterin in alopecia areata]. 53 62
16052058 2005
8
[Alopecia areata universalis and disseminated mollusca contagiosa in atopic dermatitis. Hair re-growth during treatment with interferon gamma--therapeutic effect or coincidence?]. 53 62
15892847 2005
9
Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders. 53 62
15037212 2004
10
The beneficial and detrimental effects of linoleic acid on autoimmune disorders. 53 62
15115315 2004
11
Interferon-gamma in alopecia areata. 53 62
14965793 2004
12
Therapy of alopecia areata: on the cusp and in the future. 53 62
14582675 2003
13
Selective expression of chemokine monokine induced by interferon-gamma in alopecia areata. 53 62
14632215 2003
14
Strong expression of CD40, CD54 and HLA-DR antigen and lack of evidence for direct cellular cytotoxicity are unique immunohistopathological features in alopecia areata. 53 62
12624779 2003
15
Role of the autoimmune regulator (AIRE) gene in alopecia areata: strong association of a potentially functional AIRE polymorphism with alopecia universalis. 53 62
12542742 2002
16
Epidemiology and genetics of alopecia areata. 53 62
12190641 2002
17
Interleukin-1 receptor antagonist allele 2 and familial alopecia areata. 53 62
11841553 2002
18
Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL-1L1 in alopecia areata: strong severity association and possible gene interaction. 53 62
11841485 2002
19
Association analysis of IL1A and IL1B variants in alopecia areata. 53 62
11703512 2001
20
Role of cytotoxic T cells in chronic alopecia areata. 53 62
10620125 2000
21
Alopecia areata is a T-lymphocyte mediated autoimmune disease: lesional human T-lymphocytes transfer alopecia areata to human skin grafts on SCID mice. 53 62
10674367 1999
22
Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice. 53 62
10417620 1999
23
Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. 53 62
9421466 1998
24
IFN-gamma-induced HLA-DR but not ICAM-1 expression on cultured dermal papilla cells is downregulated by TNF-alpha. 53 62
9266024 1997
25
Effects of interleukins, colony-stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areata. 53 62
8977716 1996
26
Cytokines and growth factors influence hair growth in vitro. Possible implications for the pathogenesis and treatment of alopecia areata. 53 62
8967784 1996
27
Growth factor mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. 53 62
8721483 1996
28
An allele of the interleukin-1 receptor antagonist as a genetic severity factor in alopecia areata. 53 62
7738374 1995
29
Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. 53 62
8077705 1994
30
HLA and ICAM-1 expression in alopecia areata in vivo and in vitro: the role of cytokines. 53 62
7506926 1993
31
Response of grafts from patients with alopecia areata transplanted onto nude mice, to administration of interferon-gamma. 53 62
8095867 1993
32
Aberrant intercellular adhesion molecule-1 (ICAM-1) expression by hair-follicle epithelial cells and endothelial leukocyte adhesion molecule-1 (ELAM-1) by vascular cells are important adhesion-molecule alterations in alopecia areata. 53 62
1708803 1991
33
Hair Follicle Melanocytes Initiate Autoimmunity in Alopecia Areata: a Trigger Point. 62
36121544 2022
34
Pediatric pulse dose corticosteroid therapy dosing and administration in the treatment of alopecia areata: A review of literature. 62
36461625 2022
35
Using artificial intelligence to analyze publicly available social media posts to understand patient perspectives toward specific treatments of alopecia areata. 62
36237847 2022
36
Oral tofacitinib for successful treatment of refractory alopecia areata in preschool children. 62
35876014 2022
37
Downregulation of pathogenic MICA-NKG2D interactions as a novel strategy in alopecia areata management: a new rationale for adjunct statin therapy? 62
35841295 2022
38
Alopecia areata after severe allergic contact dermatitis to a permanent hair dye. 62
35984243 2022
39
Preparation and optimization of aloe ferox gel loaded with Finasteride-Oregano oil nanocubosomes for treatment of alopecia. 62
35019794 2022
40
Evolving utility of apremilast in dermatological disorders for off-label indications. 62
35974705 2022
41
JAK: Not Just Another Kinase. 62
36252553 2022
42
Treatment Patterns and Treatment Satisfaction Among Adults with Alopecia Areata in the United States. 62
36223027 2022
43
Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors. 62
36335798 2022
44
Pediatric Game Changers∗: Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. 62
35933066 2022
45
Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy. 62
36468955 2022
46
Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases. 62
36346551 2022
47
Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients. 62
36045513 2022
48
Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study: Classification: Epidemiology. 62
35718888 2022
49
A Practical Approach to the Treatment of Alopecia Areata. 62
36386728 2022
50
Immune-mediated diseases and subsequent risk of alopecia areata in a prospective study of US women. 62
36319702 2022

Variations for Alopecia Areata

ClinVar genetic disease variations for Alopecia Areata:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TRPS1 NM_014112.5(TRPS1):c.2794G>A (p.Ala932Thr) SNV Likely Pathogenic
374202 rs1057518972 GRCh37: 8:116430587-116430587
GRCh38: 8:115418359-115418359
2 overlap with 9 genes GRCh37/hg19 18p11.32-11.31(chr18:1345040-3479168) CN LOSS Uncertain Significance
523239 GRCh37: 18:1345040-3479168
GRCh38:

Expression for Alopecia Areata

Search GEO for disease gene expression data for Alopecia Areata.

Pathways for Alopecia Areata

Pathways related to Alopecia Areata according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 ULBP3 TNF PTPN22 KLRK1 IL4 IL2RA
2
Show member pathways
13.65 TNF IL4 IL2RA IL2 IL1RN IL1R1
3
Show member pathways
13.58 ICAM1 IFNG IL17A IL1A IL1R1 IL2
4
Show member pathways
13.41 TNF IL4 IL2RA IL2 IL1R1 IL1A
5
Show member pathways
13.36 TNF IL4 IL2RA IL2 IL1RN IL1R1
6
Show member pathways
13.33 TNF PTPN22 IL4 IL2RA IL2 IL1R1
7
Show member pathways
12.69 TNF IL4 IL2RA IL2 IL1A IL17A
8
Show member pathways
12.5 TNF IL4 IL1RN IL1R1 IL1A IFNG
9
Show member pathways
12.47 IL4 IL1RN IL1R1 IL1A
10
Show member pathways
12.43 IL2RA IL2 IL1R1 IL1A
11 12.37 TNF PTPN22 IL4 IL2RA IL2 IL1RN
12
Show member pathways
12.32 TNF IL1R1 IL1A IFNG
13
Show member pathways
12.28 IL2RA IL2 ICOSLG CTLA4
14
Show member pathways
12.22 TNF IL4 IL2 IFNG
15
Show member pathways
12.22 TNF IL4 IL2 IL17A IFNG CTLA4
16 12.18 TNF IL4 IL1R1 IL1A IFNG
17
Show member pathways
12.07 IL2RA IL2 IL1R1 IL1A
18
Show member pathways
12.07 IL4 IL2RA IL2 IFNG
19 12.05 ICAM1 IL17A IL1A IL4 TNF
20 12.04 TNF KLRK1 IL4 IL2RA IL2 IFNG
21
Show member pathways
12 IL4 IL2RA IL2 IL1R1 IFNG GZMB
22
Show member pathways
11.97 TNF IL2 IL17A IFNG
23
Show member pathways
11.96 IL4 IL1R1 IL17A IFNG GZMB
24 11.86 TNF IL4 IL2 IL1R1 IL1A IFNG
25 11.84 ICAM1 IFNG IL2 IL4
26 11.83 TNF IL4 IL2 IFNG ICOSLG
27 11.8 IFNG IL17A IL2 IL2RA IL4
28 11.76 TNF IL2 IFNG
29 11.74 TNF IL1A ICAM1 GZMB
30
Show member pathways
11.74 TNF IL2 IL1A IFNG ICAM1
31 11.73 IL4 IL2 IFNG
32
Show member pathways
11.71 TNF IL4 IL2 IL1A IFNG
33 11.63 TNF IL4 IL2RA IL2 IFNG
34 11.62 IFNG IL2 IL2RA
35
Show member pathways
11.62 CTLA4 IFNG IL2 IL2RA IL4 TNF
36 11.61 IL1A IL1R1 TNF
37 11.6 IL4 IL2RA IL2 IFNG
38 11.59 TNF IL1A ICAM1
39 11.58 ICAM1 IL1A IL1R1 IL1RN TNF
40 11.56 IL4 IL2RA CTLA4
41 11.52 TNF IL1A IFNG
42 11.51 TNF KLRK1 IL4 IL2RA IL2 IL1R1
43 11.43 IL4 IL2RA IL2 IFNG
44 11.41 TNF IL4 IL17A IFNG
45
Show member pathways
11.39 TNF IL2RA IL2 IFNG GZMB
46 11.32 TNF KLRK1 IFNG GZMB
47 11.31 TNF IL1A IL17A
48 11.29 IL2RA IL2 IFNG
49 11.27 IL4 IL2 IFNG
50 11.26 TNF IL4 IL2 IL1A IFNG

GO Terms for Alopecia Areata

Cellular components related to Alopecia Areata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.58 ULBP3 TNF KLRK1 IL2RA IL1R1 IL17A

Biological processes related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 10.36 KLRK1 IL2 IL17A IFNG ICOSLG CTLA4
2 inflammatory response GO:0006954 10.34 TNF IL2RA IL1RN IL1R1 IL1A IL17A
3 positive regulation of interleukin-6 production GO:0032755 10.15 IFNG IL17A IL1A TNF
4 positive regulation of chemokine production GO:0032722 10.08 TNF IFNG AIRE
5 positive regulation of nitric oxide biosynthetic process GO:0045429 10.07 IFNG KLRK1 TNF
6 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 10.04 IL1A IL2 IL4
7 positive regulation of T cell differentiation GO:0045582 9.97 IL4 IL2RA IL2
8 positive regulation of activated T cell proliferation GO:0042104 9.97 ICOSLG IL2 IL2RA
9 natural killer cell mediated cytotoxicity GO:0042267 9.95 GZMB KLRK1 ULBP3
10 microglial cell activation GO:0001774 9.93 TNF IL4 IFNG
11 positive regulation of interleukin-23 production GO:0032747 9.92 IL17A IFNG
12 neuroinflammatory response GO:0150076 9.92 IL4 IFNG
13 natural killer cell activation GO:0030101 9.91 ULBP3 KLRK1 IL2
14 positive regulation of mononuclear cell migration GO:0071677 9.9 TNF IL4
15 positive regulation of osteoclast differentiation GO:0045672 9.88 TNF IL17A IFNG
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 IFNG IL2 IL4 TNF
17 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.84 TNF IFNG
18 positive regulation of nitrogen compound metabolic process GO:0051173 9.83 TNF IFNG
19 regulation of T cell homeostatic proliferation GO:0046013 9.81 IL2RA IL2
20 negative regulation of lymphocyte proliferation GO:0050672 9.79 IL2RA IL2
21 immune system process GO:0002376 9.76 ULBP3 PTPN22 KLRK1 IL2RA IL2 IL17A
22 regulation of CD4-positive, alpha-beta T cell proliferation GO:2000561 9.67 IL2RA IL2
23 positive regulation of type II interferon production GO:0032729 9.65 IL1R1 IL2 KLRK1 PTPN22 TNF
24 immune response GO:0006955 9.64 ULBP3 TNF IL4 IL2RA IL2 IL1RN
25 positive regulation of vitamin D biosynthetic process GO:0060557 9.62 TNF IFNG

Molecular functions related to Alopecia Areata according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.47 TNF IL4 IL2 IL1RN IL1A IL17A

Sources for Alopecia Areata

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....